Evidence map›Paper›PMID 34850056›Full record

ArticleJournal of neuropathology and experimental neurology2021

Tumor-Derived Cell Culture Model for the Investigation of Meningioma Biology.

Erik J Uhlmann, Rosalia Rabinovsky, Hemant Varma, Rachid El Fatimy, Ekkehard M Kasper, Justin M Moore, Rafael A Vega, Ajith J Thomas, Ronald L Alterman, Martina Stippler and 4 more

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Journal of neuropathology and experimental neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Erik J UhlmannFrom the Department of Neurology, Beth Israel Deaconess Hospital and Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0003-1432-4754
Rosalia RabinovskyDepartment of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Hemant VarmaDepartment of Pathology, Beth Israel Deaconess Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Rachid El FatimyDepartment of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Ekkehard M KasperDepartment of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Justin M MooreDepartment of Neurosurgery, Beth Israel Deaconess Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Rafael A VegaDepartment of Neurosurgery, Beth Israel Deaconess Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Ajith J ThomasDepartment of Neurosurgery, Beth Israel Deaconess Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Ronald L AltermanDepartment of Neurosurgery, Beth Israel Deaconess Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Martina StipplerDepartment of Neurosurgery, Beth Israel Deaconess Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Matthew P AndersonDepartment of Pathology, Beth Israel Deaconess Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Erik N UhlmannDepartment of Surgery, Hamilton General Hospital, Hamilton, Ontario, Canada.
Franciela C KipperDepartment of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Anna M KrichevskyDepartment of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Harvard University · USBrigham and Women's Hospital · USNortheastern University · US

Funding

Developing miR-10b targeting for glioblastomaR01CA215072 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI KRICHEVSKY, ANNA M. · 2018 to 2022
$2.0M
NCI NIH HHS R01 CA215072
6 · The paper itself

Abstract

Meningioma is the most common primary central nervous system tumor. Although mostly nonmalignant, meningioma can cause serious complications by mass effect and vasogenic edema. While surgery and radiation improve outcomes, not all cases can be treated due to eloquent location. Presently no medical treatment is available to slow meningioma growth owing to incomplete understanding of the underlying pathology, which in turn is due to the lack of high-fidelity tissue culture and animal models. We propose a simple and rapid method for the establishment of meningioma tumor-derived primary cultures. These cells can be maintained in culture for a limited time in serum-free media as spheres and form adherent cultures in the presence of 4% fetal calf serum. Many of the tissue samples show expression of the lineage marker PDG2S, which is typically retained in matched cultured cells, suggesting the presence of cells of arachnoid origin. Furthermore, nonarachnoid cells including vascular endothelial cells are also present in the cultures in addition to arachnoid cells, potentially providing a more accurate tumor cell microenvironment, and thus making the model more relevant for meningioma research and high-throughput drug screening.

Indexed as

Cell Culture TechniquesMeningeal NeoplasmsMeningiomaTumor Cells, CulturedHumansCultured human meningioma tumor-derived cellsMeningioma model

Identifiers

PMID34850056
PMCPMC8716066
OpenAlexW3215250261

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.